Litcius/Paper detail

An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial

Joyce F. Liu, Stéphanie Gaillard, Andrea Wahner Hendrickson, John W. Moroney, Oladapo Yeku, Elisabeth Diver, Camille C. Gunderson, Rebecca C. Arend, Elena Ratner, Vivek Samnotra, Divya Gupta, Lena Evilevitch, Sarah Wang, Ping Wang, Joseph Tang, Emeline Bacqué, Xiaohong Liu, Gottfried E. Konecny

2021Gynecologic Oncology29 citationsDOI

Topics & Concepts

MedicineInternal medicineBRCA mutationOvarian cancerOncologyOlaparibPhases of clinical researchRegimenClinical endpointBevacizumabCancerChemotherapyGastroenterologyClinical trialPolymerasePoly ADP ribose polymeraseGeneChemistryBiochemistryPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentReproductive Biology and Fertility
An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial | Litcius